冯丹;姜尔烈;

• 1:中国医学科学院血液病医院血液学研究所

摘要(Abstract)：

急性移植物抗宿主病(acute graft versus host disease,aGVHD)是异基因造血干细胞移植后特有的并发症,也是导致患者死亡的主要原因之一。间充质干细胞(mesenchymal stem cell,MSC)已被广泛研究用于aGVHD的治疗,尤其是用于经一线(类固醇)治疗后无反应的重度激素耐药aGVHD。本文通过探讨MSC治疗aGVHD是否有效、aGVHD受累器官或严重程度是否影响MSC治疗反应率、MSC体外扩增的技术问题与治疗效果之间的关系、MSC的供体来源、MSC治疗时机、输注后转归等问题研究MSC治疗的现状与未来。

关键词(KeyWords)： 间充质干细胞;急性移植物抗宿主病;重度激素耐药

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 冯丹;姜尔烈;

参考文献(References)：

• [1]Nasserreddine S,Rafei H,Elbahesh E,et al.Acute Graft Versus Host Disease:A Comprehensive Review[J].Anticancer Research,2017,37(4):1547-1555.
• [2]Ferrara JLM,Levine JE,Reddy P,et al.Graft-versus-host disease[J].Lancet,2009,373(9674):1550-1561.
• [3]Zhang B,Yeo BWY,Lai RC,et al.Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway[J].Cytotherapy,2018,20(5):687-696.
• [4]Sharma RR,Pollock K,Hubel A,et al.Mesenchymal stem or stromal cells:a review of clinical applications and manu facturing practices[J].Transfusion,2014,54(5):1418-1437.
• [5]Lysák D,KoutováL,HolubováM,et al.The Quality Control of Mesenchymal Stromal Cells by in Vitro Testing of Their Immunomodulatory Effect on Allogeneic Lymphocytes[J].Folia Biol(Praha),2016,62(3):120-130.
• [6]Le Blanc K,Frassoni F,Ball L,et al.Mesenchymal stem cells for treatment of steroid-resistant,severe,acute graft-versus-host disease:a phaseⅡstudy[J].Lancet,2008,371(9624):1579-1586.
• [7]Resnick IB,Barkats C,Shapira MY,et al.Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells(MSC)[J].Am J Blood Res,2013,3(3):225-238.
• [8]Salmenniemi U,It?l?-Remes M,Nystedt J,et al.Good responses but high TRM in adult patients after MSC therapy for Gv HD[J].Bone Marrow Transplant,2017,52(4):606-608.
• [9]Introna M,Lucchini G,Dander E,et al.Treatment of graft versus host disease with mesenchymal stromal cells:a phase Istudy on 40 adult and pediatric patients[J].Biol Blood Marrow Transplant,2014,20(3):375-381.
• [10]Kallekleiv M,Larun L,Bruserud O,et al.Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation:A systematic review and meta-analysis[J].Cytotherapy,2016,18(2):172-185.
• [11]Dander E,Lucchini G,Vinci P,et al.Mesenchymal stromal cells for the treatment of graft-versus-host disease:understanding the in vivo biological effect through patient imm une monitoring[J].Leukemia,2012,26(7):1681-1684.
• [12]von Bahr L,Sundberg B,L?nnies L,et al.Long-term complications,immunologic effects,and role of passage for outcome in mesenchymal stromal cell therapy[J].Biol Blood Marrow Transplant,2012,18(4):557-564.
• [13]Dotoli GM,Santis GD,Orellana MD,et al.Mesenchymal stromal cell infusion to treat steroid-refractory acute Gv HDⅢ/Ⅳafter hematopoietic stem cell transplantation[J].Bone Marrow Transplant,2017,52(6):859-862.
• [14]Zhao K,Lou R,Huang F,et al.Immunomodulation Effects of Mesenchymal Stromal Cells on Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant,2015,21(1):97-104.
• [15]Samuelsson H,Ringdén O,L?nnies H,et al.Optimizing in vitro conditions for immunomodulation and expansion of mesen chymal stromal cells[J].Cytotherapy,2009,11(2):129-136.
• [16]Munneke JM,Spruit MJ,Cornelissen AS,et al.The Potential of Mesenchymal Stromal Cells as Treatment for Severe SteroidRefractory Acute Graft-Versus-Host Disease:A Critical Review of the Literature[J].Transplantation,2016,100(11):2309-2314.
• [17]Bozda?SC,Tekgündüz E,Altunta?F.Treatment of acute graft versus host disease with mesancyhmal stem cells:Questions and answers[J].Transfus Apher Sci,2016,54(1):71-75.
• [18]Kebriaei P,Isola L,Bahceci E,et al.Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease[J].Biol Blood Marrow Transplant,2009,15(7):804-811.
• [19]Rizk M,Monaghan M,Shorr R,et al.Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graftversus-Host Disease:A Scoping Review of the Evidence[J].Biol Blood Marrow Transplant,2016,22(8):1416-1423.
• [20]Jurado M,De La Mata C,Ruiz-García A,et al.Adipose tissuederived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease:A phaseⅠ/Ⅱstudy[J].Cytoth erapy,2017,19(8):927-936.
• [21]Audehm S,Krackhardt AM.Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation[J].Oncol Res Treat,2017,40(11):691-696.
• [22]Nishia Y,Murakamib A,Murayama Y,et al.Adipose tissuederived mesenchymal stem cells ameliorate bone marrow aplasia related with graft-versus-host disease in experimental murine models[J].Transpl Immunol,2019,55:101205.
• [23]Baygan1 A,Aronsson-Kurttila1 W,Morettila G,et al.Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis[J].Front.Immunol,2017,8:795.
• [24]Bernardo ME,Avanzini MA,Ciccocioppo R,et al.Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease[J].Cytotherapy,2009,11(7):825-836.
• [25]Ball LM,Bernardo ME,Roelofs H,et al.Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory,grade III-IV acute graft-versushost disease[J].Br J Haematol,2013,163(4):501-509.
• [26]Liew A,O'Brien T,Egan L.Mesenchymal stromal cell therapy for Crohn's disease[J].Dig Dis,2014,32(suppl 1):50-60.
• [27]Abman SH,Matthay MA.Mesenchymal stem cells for the preve ntion of bronchopulmonary dysplasia:delivering the secretome[J].Am J Respir Crit Care Med,2009,180(11):1039-1041.
• [28]Ko?ON,Gerson SL,Cooper BW,et al.Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast[J].J Clin Oncol,2000,18(2):307-316.
• [29]Villaron EW,Almeida J,López-Holgado H,et al.Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation[J].Haematologica,2004,89(12):1421-1427.
• [30]Fouillard L,Bensidhoum M,Bories D,et al.Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma[J].Leukemia,2003,17(2):474-476.
• [31]von Bahr L,Batsis I,Moll G,et al.Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation[J].Stem Cells,2012,30(7):1575-1578.
• [32]CléDV,Santana-Lemos B,Tellechea MF,et al.Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia[J].Cytotherapy,2015,17(12):1696-1705.
• [33]Davies LC,Boberg E,Le Blanc K,et al.Commentary:Role of Mesenchymal Stromal Cell-Mediated Crosstalk with Macrophages in Graft-versus-Host Disease and Tissue Repair[J].Biol Blood Marrow Transplant,2017,23(6):861-862.
• [34]Fujii,Miura,Fujishiro,et al.AGraft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Perip heral Preservation of Naive T Cell Populations[J].Stem Cells,2018,36(3):434-445.
• [35]Bader P,Ku?i Z,Bakhtiar S,et al.Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product(MSC-FFM)[J].Bone Marrow Transplantation,2018,53(7):852-862.
• [36]Bouchlaka MN,Moffitt AB,Kim J,et al.Human Mesenchymal Stem Cell-Educated Macrophages Are a Distinct High IL-6-Producing Subset that Confer Protection in Graft-versus-HostDisease and Radiation Injury Models[J].Biol Blood Marrow Transplant,2017,23(6):897-905.
• [37]Rasko JEJ,Patel A,Griffin JE,et al.Results of the First Completed Clinical Trial of an i PSC-Derived Product:CYP-001 in Steroid-Resistant Acute Gv HD[J].Biol Blood Marrow Transplant,2019,25:255-256.